According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 3.46%.

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.92% to $485.89 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to ...

Will these developments be enough to sustain the rally? Let's discuss whether Vertex Pharmaceuticals stock is a buy now. The past year has been transformative for Vertex, marked by the launch of ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...